5H-Benzo[b]carbazole

Base Information

• Chemical Name: 5H-Benzo[b]carbazole
• CAS No.: 243-28-7
• Molecular Formula: C16H11 N
• Molecular Weight: 217.27
• Hs Code.: 2933990090
• European Community (EC) Number: 205-953-8
• NSC Number: 59788
• UNII: S1VP75HP3Y
• DSSTox Substance ID: DTXSID80179026
• Nikkaji Number: J193.687E
• Wikidata: Q83049547
• Mol file: 243-28-7.mol

Synonyms:5H-Benzo[b]carbazole;243-28-7;2,3-Benzocarbazole;2,3-Benzcarbazole;Benzo(b)carbazole;5H-BENZO(B)CARBAZOLE;benzo[b]carbazole;S1VP75HP3Y;EINECS 205-953-8;NSC 59788;NSC-59788;NSC59788;5H-benzo[b]carbazol;UNII-S1VP75HP3Y;SCHEMBL5716702;3-Butyl-2-fluoro-1-tosylindole;DTXSID80179026;MFCD02316988;AKOS024376337;AS-44333

Chemical Property of 5H-Benzo[b]carbazole

Chemical Property:

• Vapor Pressure: 4.5E-08mmHg at 25°C
• Melting Point: 330-331 °C
• Boiling Point: 456.1°C at 760 mmHg
• PKA: 17.00±0.30(Predicted)
• Flash Point: 207.9°C
• PSA: 15.79000
• Density: 1.277g/cm³
• LogP: 4.47430
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• XLogP3: 4.3
• Hydrogen Bond Donor Count: 1
• Hydrogen Bond Acceptor Count: 0
• Rotatable Bond Count: 0
• Exact Mass: 217.089149355
• Heavy Atom Count: 17
• Complexity: 287

Purity/Quality:

98%, ^*data from raw suppliers

5H-Benzo[b]carbazole 95+% ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1=CC=C2C=C3C(=CC2=C1)C4=CC=CC=C4N3

Technology Process of 5H-Benzo[b]carbazole

There total 44 articles about 5H-Benzo[b]carbazole which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield: 86.0%

C16H12BrN → 2,3-benzocarbazole (243-28-7)

Guidance literature:

With palladium on activated charcoal; sodium carbonate; In ethanol; at 72 ℃; for 6h; Reflux;

Reference yield: 83.0%

5-(pyridin-2-yl)-5H-benzo[b]carbazole → 2,3-benzocarbazole (243-28-7)

Guidance literature:

5-(pyridin-2-yl)-5H-benzo[b]carbazole; With methyl trifluoromethanesulfonate; In dichloromethane; at 0 - 20 ℃; for 24h;

With water; sodium hydroxide; In methanol; at 60 ℃; for 12h;

DOI:10.1021/acs.orglett.1c02709

Reference yield: 80.0%

6,11-dihydro-5H-benzocarbazole (22044-93-5) → 2,3-benzocarbazole (243-28-7)

Guidance literature:

With 2,3-dicyano-5,6-dichloro-p-benzoquinone; In benzene; for 14h; Heating;

upstream raw materials:

(2-methyl-1H-indol-3-yl)phenylmethanone

1-(naphthalen-2-yl)-1H-benzo[d][1,2,3]triazole

N-Phenyl-2-naphthylamine

3-[2]naphthyl-3H-benzotriazole-4-carboxylic acid

Downstream raw materials:

benzene-1,2-dicarboxylic acid

Refernces

Kinase scaffold repurposing for neglected disease drug discovery: Discovery of an efficacious, lapatanib-derived lead compound for trypanosomiasis

10.1021/jm400349k

This research presents the repurposing of kinase scaffolds for the discovery of new drugs to combat neglected tropical diseases, specifically focusing on human African trypanosomiasis (HAT), a disease caused by the protozoan parasite Trypanosoma brucei. The study aims to expedite drug discovery by utilizing chemical scaffolds from drugs approved for other indications, demonstrating the potential of lapatinib and canertinib, two 4-anilinoquinazolines with low micromolar EC50 values against T. brucei. The researchers synthesized and tested several potent 4-anilinoquinazolines, leading to the identification of NEU617 (23a), a highly potent and orally bioavailable inhibitor of trypanosome replication. The compound 23a was found to block kinetoplast duplication and arrest cytokinesis in trypanosomes, offering a new chemical tool for studying the regulation of the trypanosome cell cycle. The study concludes that compounds based on established human EGFR inhibitor chemotypes can be effective against HAT and that further optimization of these chemotypes is necessary to improve their pharmacokinetic properties and effectiveness in treating HAT. The chemicals used in the process include a series of 4-anilinoquinazoline derivatives, with lapatinib (GW572016, 1) and canertinib (CI-1033) as the starting points for optimization.